Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 21, 2017
Pharmacy Choice - Pharmaceutical News - Array Biopharma's 12% Drop, Explained - November 21, 2017

Pharmacy News Article

 3/20/17 - Array Biopharma's 12% Drop, Explained

Shares of Array Biopharma Inc (NASDAQ: ARRY), a biopharmaceutical company that focuses on drugs to treat patients suffering from cancer, lost more than 12 percent early Monday morning after announcing a disappointing update to one of its therapies.

Array Biopharma announced in a press release that the new drug application (NDA) for its binimetinib monotherapy for the treatment of a rare subset of skin cancer has been withdrawn from the U.S. Food and Drug Administration's (FDA) Division of Oncology Products 2 (DOP2).

Array BioPharma saw its stock soar more than 80 percent in one day in September of 2016 after announcing encouraging results from its late-stage skin cancer drug. Specifically, the median PFS for patients treated with a combination of encorafenib plus binimetinib was 14.9 months versus 7.3 months for patients treated with vemurafenib.

Withdrawing NDA

Array Biopharma's press release on Monday noted that its decision to withdraw its NDA was based on discussions and communications with the FDA, including a late cycle review meeting which was held on Friday.

Based on the discussions with the FDA, Array BioPharma's management concluded that the benefits demonstrated in an ongoing Phase 3 clinical trial called NEMO isn't strong enough to support approval of the therapy.

Nevertheless, ongoing clinical trials for the aforementioned binimetinib in combination with encorafenib will proceed as planned with Phase 3 results on track to be delivered in mid-2017.

Related Links:

Getting Into The Drug Business: From NDAs To PDUFA Dates

Getting Into The Business Of Medical Marijuana: An Interview With IGC CEO Ram Mukunda

Write to with any questions about this content. Subscribe to Benzinga Pro:

© 2015 Benzinga Newswires. Benzinga does not provide investment advice. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Last Chance
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Nov 29: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement